China Resources Pharmaceutical Group (SEHK:3320) Balance Sheet Analysis 2013-2025

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Metric	2024	2025
Total Cash And Short-Term Investments	HK$17.477B	HK$58.732B
Net Receivables	HK$108.184B	HK$113.231B
Inventory	HK$39.427B	HK$48.196B
Prepaid Expenses And Other Current Assets	HK$4.076B	HK$4.462B
Other Current Assets	HK$28.589B	HK$0.042B
Total Current Assets	HK$197.753B	HK$224.664B
Property, Plant And Equipment	HK$26.339B	HK$36.1B
Goodwill And Intangible Assets	HK$30.909B	HK$39.59B
Long-Term Investments	HK$6.537B	HK$9.958B
Deferred Tax Assets	-	HK$2.645B
Other Noncurrent Assets	HK$12.737B	HK$5.384B
Total Noncurrent Assets	HK$76.522B	HK$93.676B
Other Assets	-	-
Total Assets	HK$274.275B	HK$318.341B

Metric	2024	2025
Total Payables	HK$62.353B	HK$48.727B
Accrued Expenses	-	HK$4.692B
Short-Term Debt	HK$47.727B	HK$80.278B
Current Portion Of Lease Obligations	HK$520.268M	-
Income Taxes Payable	-	-
Current Deferred Revenue	-	HK$4.613B
Other Current Liabilities	HK$30.094B	HK$20.084B
Total Current Liabilities	HK$140.693B	HK$158.395B
Long-Term Debt	HK$23.515B	HK$22.963B
Capital Lease Obligations	HK$1.338B	HK$0.813B
Noncurrent Deferred Revenue	HK$713.716M	-
Noncurrent Deferred Tax Liabilities	HK$2.038B	HK$2.374B
Other Noncurrent Liabilities	HK$1.266B	HK$2.159B
Total Noncurrent Liabilities	HK$29.21B	HK$29.122B
Other Liabilities	-	-
Total Liabilities	HK$169.903B	HK$187.516B

Metric	2024	2025
Treasury Stock	-	-
Preferred Stock	-	-
Common Stock	HK$26.209B	HK$27.434B
Retained Earnings	HK$32.986B	-
Additional Paid-In Capital	-	-
Accumulated Other Comprehensive Income	HK$-7.856B	-
Other Stockholders' Equity	-	HK$29.826B
Total Common Stockholders' Equity	HK$51.335B	HK$57.259B
Minority Interest	HK$53.037B	HK$73.565B
Total Equity	HK$104.372B	HK$130.824B
Total Liabilities And Equity	HK$274.275B	HK$318.341B

Metric	2024	2025
Total Investments	HK$6.537B	HK$38.084B
Total Debt	HK$73.426B	HK$104.867B
Net Debt	HK$55.949B	HK$74.261B

China Resources Pharmaceutical Group Balance Sheet

Balance Sheet Composition